• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending.

作者信息

Huang Tao, Wagner Anita Katharina, Bai Lin, Huang Cong, Guan Xiaodong, Shi Luwen

机构信息

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, P. R. China.

Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, 02215, USA.

出版信息

Cancer Commun (Lond). 2021 Apr;41(4):345-348. doi: 10.1002/cac2.12144. Epub 2021 Feb 20.

DOI:10.1002/cac2.12144
PMID:33609064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8045901/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af53/8045901/4837a7bfcc9a/CAC2-41-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af53/8045901/4837a7bfcc9a/CAC2-41-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af53/8045901/4837a7bfcc9a/CAC2-41-345-g001.jpg

相似文献

1
Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending.中国的抗癌药物：每日治疗费用、相对采购量及支出趋势。
Cancer Commun (Lond). 2021 Apr;41(4):345-348. doi: 10.1002/cac2.12144. Epub 2021 Feb 20.
2
Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.促进创新抗癌药物的可及性：中国药品价格与国家医保谈判综述。
Inquiry. 2023 Jan-Dec;60:469580231170729. doi: 10.1177/00469580231170729.
3
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.政府报销谈判对中国靶向抗癌药物价格、数量和支出的影响。
BMJ Glob Health. 2021 Jul;6(7). doi: 10.1136/bmjgh-2021-006196.
4
Access to anticancer medicines in public hospitals of Northwestern China.中国西北地区公立医院的抗癌药物可及性。
Front Public Health. 2023 May 19;11:1182617. doi: 10.3389/fpubh.2023.1182617. eCollection 2023.
5
Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.国家药品价格谈判政策对中国抗癌药物的利用、成本和可及性的影响：一项基于对照的中断时间序列研究。
J Glob Health. 2022 Dec 17;12:11016. doi: 10.7189/jogh.12.11016.
6
Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.抗癌药物的可及性、价格和可负担性：来自中国江苏省两项横断面调查的证据。
Int J Environ Res Public Health. 2019 Oct 3;16(19):3728. doi: 10.3390/ijerph16193728.
7
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.中国国家医保谈判抗癌药的价格和临床获益。
Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7. Epub 2022 Jun 29.
8
The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.价格谈判对中等收入国家公共采购价格及8种创新癌症药物可及性的影响：以墨西哥为例
Value Health Reg Issues. 2019 Dec;20:129-135. doi: 10.1016/j.vhri.2019.04.006. Epub 2019 Jul 30.
9
Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China.基本药物向基层医疗机构的配送及其与采购量和价格的关联：中国湖北省的案例研究
Appl Health Econ Health Policy. 2017 Feb;15(1):57-64. doi: 10.1007/s40258-016-0276-8.
10
Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer.癌症 Medicare 受益人群中高成本靶向口服抗癌药物带来的日益增长的经济负担。
JCO Oncol Pract. 2022 Nov;18(11):e1739-e1749. doi: 10.1200/OP.22.00171. Epub 2022 Sep 13.

引用本文的文献

1
Assessment of the implementation of accelerated drug marketing registration procedures for antineoplastic and immunomodulating agents in China: based on 2016-2022 review data.中国抗肿瘤和免疫调节药物加速上市注册程序实施情况评估：基于2016 - 2022年审评数据
Front Pharmacol. 2024 Mar 18;15:1345672. doi: 10.3389/fphar.2024.1345672. eCollection 2024.
2
Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016-2020: a retrospective observational study based on inpatient and outpatient hospital data.2016-2020 年中国九个主要城市肺癌患者抗肿瘤药物使用、费用和处方模式趋势：基于住院和门诊医院数据的回顾性观察研究。
BMJ Open. 2023 Mar 17;13(3):e069645. doi: 10.1136/bmjopen-2022-069645.
3

本文引用的文献

1
Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.医疗保险处方药部分中受保护药物的价格相对于通货膨胀的增长，2012-2017 年。
JAMA. 2019 Jul 16;322(3):267-269. doi: 10.1001/jama.2019.7521.
2
Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version).《中国乳腺癌诊疗规范（2018年版）》（英文版）
Chin J Cancer Res. 2019 Apr;31(2):259-277. doi: 10.21147/j.issn.1000-9604.2019.02.02.
3
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.2016-2020 年中国国家药品监督管理局批准的实体瘤新药的价值评估。
Front Public Health. 2023 Feb 24;11:1109668. doi: 10.3389/fpubh.2023.1109668. eCollection 2023.
南非 14 年来药品招标对价格和市场集中的影响。
Soc Sci Med. 2019 Jan;220:362-370. doi: 10.1016/j.socscimed.2018.11.029. Epub 2018 Nov 23.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.2003-2015 年期间中国癌症生存率变化：基于 17 个癌症登记处的汇总分析。
Lancet Glob Health. 2018 May;6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X.
6
National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.法国口服抗癌药物的使用情况及费用的全国趋势：一项基于人群的8年研究。
Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1233-1241. doi: 10.1002/pds.4282. Epub 2017 Aug 3.
7
Entry time effects and follow-on drug competition.进入时间效应和后续药物竞争。
Eur J Health Econ. 2016 Jan;17(1):45-60. doi: 10.1007/s10198-014-0654-9. Epub 2014 Dec 12.
8
Rising cost of anticancer drugs in Australia.澳大利亚抗癌药物成本不断上涨。
Intern Med J. 2014 May;44(5):458-63. doi: 10.1111/imj.12399.